OBJECTIVE： To explore the characteristics and regularities of the adverse drug reactions （ADRs） induced by irinotecan， in order to provide reference for clinical application. METHODS： In retrospective study， 56 cases of irinotecan-induced ADR collected from our hospital during Jun. 2011-Jan.2015 were analyzed statistically in respects of gender， age， disease types， ECOG score， medication， organs/systems involved in ADR， clinical manifestations， outcome， etc. RESULTS： All 56 patients suffered from ADR， among which the percentage of hematopoietic system accounted for the highest （100％）， and followed by digestive system； the grade Ⅰ-Ⅱ ADRs accounted for 87.20％， the grade Ⅲ-Ⅳ ADRs accounted for 12.80％. 64.50％ of ADRs occurred within 1 week. In respect of conversion， 85.71％ （48/56） of the patients recovered with supportive care and continued chemotherapy， the remaining 8 cases had to reduce the dose of chemotherapy and then recovered. CONCLUSIONS： With regular dose， irinotecan is well tolerated. Since ADRs induced by irinotecan are slight， all the ADRs are well managed. It is important to enhance follow-up observations of patients to prevent some serious ADRs.